Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. CapMan Oy and 3i Group – sale of NeoPharma AB to Solvay Pharmaceuticals
Mandate

CapMan Oy and 3i Group – sale of NeoPharma AB to Solvay Pharmaceuticals

May 10, 2005

Solvay Pharmaceuticals, the Belgium based pharmaceuticals firm, has agreed to acquire NeoPharma AB, the Sweden based pharmaceuticals firm involved in development of drugs for the treatment of Parkinson's disease, from 3i Group plc, the UK based private equity firm, and CapMan, the Finnish private equity firm, in a transaction, for approximately SEK 640m (EUR 71.26m).

Vinge acted for the sellers, being private investors as well as private equity funds including 3i and CapMan.
Anders Åberg, Malin Ohlin Åkermark (reponsible partners)
Maja Wettergren, Ola Sandersson (associates)

Related

Vinge advises as Nimlas expands with dual acquisitions in the electrical sector

 Vinge has advised Nimlas in connection with the acquisitions of Uppsala Elcentral AB and Tjädermo's El AB – two strategic transactions that strengthen the group's position in the Swedish electrical installation market.
February 20, 2026

Vinge advises Zengun in connection with its issuance of bonds in an amount of SEK 750 million and its early redemption of outstanding bonds

 Vinge has advised Zengun Group AB (publ) in connection with its issuance of senior secured bonds in an amount of SEK 750 million (within a framework of SEK 1,500 million) and in parallel with the company's voluntary early redemption of previously issued bonds.
February 20, 2026

Vinge has advised Sluta Gräva in connection with its acquisition of Stavrex

 Vinge has advised Sluta Gräv, a portfolio company of Sobro, in connection with the acquisition of Stavrex. Together, the companies form the Nordic region’s leading supplier of ground screws, with the market’s broadest offering.
February 18, 2026